Henry Schein (NASDAQ:HSIC) Releases Earnings Results, Beats Estimates By $0.09 EPS

Henry Schein (NASDAQ:HSIC) issued its quarterly earnings data on Tuesday. The company reported $1.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.09, Briefing.com reports. The firm had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.21 billion. Henry Schein had a net margin of 3.37% and a return on equity of 14.03%. Henry Schein’s revenue was up 3.7% on a year-over-year basis. During the same period in the previous year, the firm earned $1.21 EPS. Henry Schein updated its FY24 guidance to $5.00 to $5.16 EPS.

Henry Schein Trading Up 2.2 %

HSIC opened at $72.76 on Thursday. The business has a fifty day moving average price of $73.01 and a 200 day moving average price of $72.34. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.67 and a quick ratio of 1.00. Henry Schein has a 12 month low of $60.01 and a 12 month high of $82.63. The stock has a market capitalization of $9.35 billion, a price-to-earnings ratio of 23.10, a PEG ratio of 1.68 and a beta of 0.87.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on HSIC shares. TheStreet raised shares of Henry Schein from a “c+” rating to a “b-” rating in a research note on Monday, February 26th. Jefferies Financial Group boosted their target price on Henry Schein from $74.00 to $81.00 and gave the company a “hold” rating in a research report on Wednesday, March 6th. SVB Leerink started coverage on Henry Schein in a research report on Monday, February 26th. They set a “market perform” rating and a $78.00 price target for the company. Evercore ISI lifted their price objective on Henry Schein from $79.00 to $83.00 and gave the company an “in-line” rating in a research note on Wednesday, February 28th. Finally, Piper Sandler increased their target price on Henry Schein from $78.00 to $86.00 and gave the stock an “overweight” rating in a research note on Monday, February 26th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $81.73.

Insider Buying and Selling at Henry Schein

In other news, Vice Chairman James P. Breslawski sold 2,907 shares of the business’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $74.37, for a total transaction of $216,193.59. Following the completion of the transaction, the insider now directly owns 209,562 shares of the company’s stock, valued at $15,585,125.94. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Henry Schein news, CEO Bradford C. Connett sold 6,430 shares of the firm’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total value of $477,620.40. Following the sale, the chief executive officer now directly owns 73,108 shares in the company, valued at $5,430,462.24. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Vice Chairman James P. Breslawski sold 2,907 shares of the company’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $74.37, for a total value of $216,193.59. Following the transaction, the insider now directly owns 209,562 shares of the company’s stock, valued at $15,585,125.94. The disclosure for this sale can be found here. 1.14% of the stock is owned by corporate insiders.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.